Literature DB >> 30072579

Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.

Lilli Saarinen1, Pirjo Nummela1, Hannele Leinonen1, Annamari Heiskanen2, Alexandra Thiel1, Caj Haglund3,4, Anna Lepistö3, Tero Satomaa2, Sampsa Hautaniemi1, Ari Ristimäki5,6.   

Abstract

Pseudomyxoma peritonei (PMP) is a subtype of mucinous adenocarcinoma that most often originates from the appendix, and grows in the peritoneal cavity filling it with mucinous ascites. KRAS and GNAS mutations are frequently found in PMP, but other common driver mutations are infrequent. As altered glycosylation can promote carcinogenesis, we compared N-linked glycan profiles of PMP tissues to those of normal appendix. Glycan profiles of eight normal appendix samples and eight low-grade and eight high-grade PMP specimens were analyzed by mass spectrometry. Our results show differences in glycan profiles between PMP and the controls, especially in those of neutral glycans, and the most prominent alteration was increased fucosylation. We further demonstrate up-regulated mRNA expression of four fucosylation-related enzymes, the core fucosylation performing fucosyltransferase 8 and three GDP-fucose biosynthetic enzymes in PMP tissues when compared with the controls. Up-regulated protein expression of the latter three enzymes was further observed in PMP cells by immunohistochemistry. We also demonstrate that restoration of fucosylation either by salvage pathway or by introduction of an expression of intact GDP-mannose 4,6-dehydratase enhance expression of MUC2, which is the predominant mucin molecule secreted by the PMP cells, in an intestinal-derived adenocarcinoma cell line with defective fucosylation because of deletion in the GDP-mannose 4,6-dehydratase gene. Thus, altered glycosylation especially in the form of fucosylation is linked to the characteristic mucin production of PMP. Glycomic data are available via ProteomeXchange with identifier PXD010086.
© 2018 Saarinen et al.

Entities:  

Keywords:  GNAS; Gastrointestinal disease; Gene Expression; Glycomics; Glycosylation; Immunohistochemistry; Mass Spectrometry; fucosylation; mucin; pseudomyxoma peritonei

Mesh:

Substances:

Year:  2018        PMID: 30072579      PMCID: PMC6210226          DOI: 10.1074/mcp.RA118.000615

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  50 in total

1.  Fucosylation is associated with the malignant transformation of intraductal papillary mucinous neoplasms: a lectin microarray-based study.

Authors:  Kiminori Watanabe; Masayuki Ohta; Kazuhiro Yada; Yoko Komori; Yukio Iwashita; Kenji Kashima; Masafumi Inomata
Journal:  Surg Today       Date:  2016-01-11       Impact factor: 2.549

2.  α(1,6)Fucosyltransferase expression is an independent prognostic factor for disease-free survival in colorectal carcinoma.

Authors:  L Muinelo-Romay; S Villar-Portela; E Cuevas Alvarez; E Gil-Martín; Almudena Fernández-Briera
Journal:  Hum Pathol       Date:  2011-06-08       Impact factor: 3.466

3.  Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling.

Authors:  Xiangchun Wang; Jianguo Gu; Hideyuki Ihara; Eiji Miyoshi; Koichi Honke; Naoyuki Taniguchi
Journal:  J Biol Chem       Date:  2005-11-29       Impact factor: 5.157

4.  Analysis of the human cancer glycome identifies a novel group of tumor-associated N-acetylglucosamine glycan antigens.

Authors:  Tero Satomaa; Annamari Heiskanen; Iréne Leonardsson; Jonas Angström; Anne Olonen; Maria Blomqvist; Noora Salovuori; Caj Haglund; Susann Teneberg; Jari Natunen; Olli Carpén; Juhani Saarinen
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

5.  Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.

Authors:  Xiaoying Liu; Kabir Mody; Francine B de Abreu; J Marc Pipas; Jason D Peterson; Torrey L Gallagher; Arief A Suriawinata; Gregory H Ripple; Kathryn C Hourdequin; Kerrington D Smith; Richard J Barth; Thomas A Colacchio; Michael J Tsapakos; Bassem I Zaki; Timothy B Gardner; Stuart R Gordon; Christopher I Amos; Wendy A Wells; Gregory J Tsongalis
Journal:  Clin Chem       Date:  2014-05-12       Impact factor: 8.327

Review 6.  Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer.

Authors:  Stefan Mereiter; Meritxell Balmaña; Joana Gomes; Ana Magalhães; Celso A Reis
Journal:  Front Oncol       Date:  2016-03-09       Impact factor: 6.244

7.  Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs.

Authors:  Lei Cheng; Shuhang Gao; Xiaobo Song; Weijie Dong; Huimin Zhou; Lifen Zhao; Li Jia
Journal:  Oncotarget       Date:  2016-09-20

8.  Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.

Authors:  Lilli Saarinen; Pirjo Nummela; Alexandra Thiel; Rainer Lehtonen; Petrus Järvinen; Heikki Järvinen; Lauri A Aaltonen; Anna Lepistö; Sampsa Hautaniemi; Ari Ristimäki
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

9.  Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis.

Authors:  Terence T Sio; Aaron S Mansfield; Travis E Grotz; Rondell P Graham; Julian R Molina; Florencia G Que; Robert C Miller
Journal:  J Hum Genet       Date:  2013-12-26       Impact factor: 3.172

10.  2016 update of the PRIDE database and its related tools.

Authors:  Juan Antonio Vizcaíno; Attila Csordas; Noemi del-Toro; José A Dianes; Johannes Griss; Ilias Lavidas; Gerhard Mayer; Yasset Perez-Riverol; Florian Reisinger; Tobias Ternent; Qing-Wei Xu; Rui Wang; Henning Hermjakob
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

View more
  2 in total

Review 1.  Recent Advances in Glycoproteomic Analysis by Mass Spectrometry.

Authors:  Suttipong Suttapitugsakul; Fangxu Sun; Ronghu Wu
Journal:  Anal Chem       Date:  2019-11-04       Impact factor: 6.986

2.  N-glycomic profiling of colorectal cancer according to tumor stage and location.

Authors:  Matilda Holm; Pirjo Nummela; Annamari Heiskanen; Tero Satomaa; Tuomas Kaprio; Harri Mustonen; Ari Ristimäki; Caj Haglund
Journal:  PLoS One       Date:  2020-06-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.